STOCK TITAN

[144] CryoPort, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

CryoPort, Inc. (CYRX) Form 144 notice: The filing reports a proposed sale of 9,300 common shares, with an aggregate market value of $80,617.98, from a total of 50,066,968 shares outstanding. The shares are to be sold on 08/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states the shares were acquired on 08/19/2025 by exercise of options under a registered plan and were paid for in cash. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Avviso Form 144 di CryoPort, Inc. (CYRX): La dichiarazione segnala la proposta vendita di 9.300 azioni ordinarie, per un valore complessivo di mercato di $80.617,98, su un totale di 50.066.968 azioni in circolazione. Le azioni saranno vendute il 08/19/2025 sul NASDAQ tramite Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. Il documento indica che le azioni sono state acquisite il 08/19/2025 mediante esercizio di opzioni previste da un piano registrato e pagate in contanti. Il dichiarante riferisce di non aver venduto titoli negli ultimi tre mesi e conferma l'assenza di informazioni materiali avverse non divulgate.

Aviso Form 144 de CryoPort, Inc. (CYRX): La presentación informa sobre la propuesta de venta de 9.300 acciones ordinarias, con un valor de mercado agregado de $80.617,98, de un total de 50.066.968 acciones en circulación. Las acciones se venderán el 08/19/2025 en el NASDAQ a través de Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. La declaración indica que las acciones se adquirieron el 08/19/2025 mediante el ejercicio de opciones bajo un plan registrado y se pagaron en efectivo. El declarante informa que no vendió valores en los últimos tres meses y afirma que no existe información adversa material no divulgada.

CryoPort, Inc. (CYRX) Form 144 공지: 제출 서류는 총 발행주식 50,066,968주 중 9,300 보통주를 매도할 예정이며, 총 시장가치는 $80,617.98라고 보고합니다. 해당 주식은 08/19/2025NASDAQ에서 Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY를 통해 매도될 예정입니다. 서류에 따르면 주식은 08/19/2025에 등록된 플랜에 따른 옵션 행사로 취득되었고 현금으로 지급되었다고 합니다. 제출자는 최근 3개월간 매도한 증권이 없음을 보고하고, 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.

Avis Form 144 de CryoPort, Inc. (CYRX) : Le dépôt signale la vente proposée de 9 300 actions ordinaires, pour une valeur marchande totale de 80 617,98 $, sur un total de 50 066 968 actions en circulation. Les actions doivent être vendues le 08/19/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. Le document indique que les actions ont été acquises le 08/19/2025 par exercice d’options dans le cadre d’un plan enregistré et ont été payées en espèces. Le déclarant indique n’avoir vendu aucun titre au cours des trois derniers mois et affirme qu’il n’existe aucune information défavorable matérielle non divulguée.

Form 144-Mitteilung von CryoPort, Inc. (CYRX): Die Einreichung meldet einen geplanten Verkauf von 9.300 Stammaktien mit einem kumulierten Marktwert von $80.617,98 aus insgesamt 50.066.968 ausstehenden Aktien. Die Aktien sollen am 08/19/2025 an der NASDAQ über Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY verkauft werden. In der Einreichung heißt es, die Aktien seien am 08/19/2025 durch Ausübung von Optionen im Rahmen eines registrierten Plans erworben und in Barkasse bezahlt worden. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und bestätigt, dass keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.

Positive
  • Transaction documented under Rule 144: Notice filed indicating compliance with Rule 144 sale procedures.
  • Acquisition and payment disclosed: Shares were acquired by exercise of options under a registered plan and paid for in cash on 08/19/2025.
  • Broker-dealer identified: Sale to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
Negative
  • None.

Insights

TL;DR: Insider-originated sale via Rule 144 after option exercise; transaction appears routine and compliance-focused.

The Form 144 discloses a notice to sell 9,300 common shares through a registered broker-dealer on 08/19/2025. The shares were acquired the same day through exercise of options under a registered plan and paid in cash, and the filer indicates no sales in the prior three months. From a securities-market perspective, this is a standard Rule 144 disclosure for an affiliate disposing of shares following an option exercise and uses an established brokerage channel.

TL;DR: Disclosure follows Rule 144 mechanics and includes the required attestation about material non-disclosure.

The filing includes the statutory representation that the seller does not possess undisclosed material adverse information and notes no prior three-month sales. It also documents acquisition details (exercise under a registered plan) and payment method (cash), which align with routine insider transaction reporting and internal governance expectations for transparency around equity disposals.

Avviso Form 144 di CryoPort, Inc. (CYRX): La dichiarazione segnala la proposta vendita di 9.300 azioni ordinarie, per un valore complessivo di mercato di $80.617,98, su un totale di 50.066.968 azioni in circolazione. Le azioni saranno vendute il 08/19/2025 sul NASDAQ tramite Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. Il documento indica che le azioni sono state acquisite il 08/19/2025 mediante esercizio di opzioni previste da un piano registrato e pagate in contanti. Il dichiarante riferisce di non aver venduto titoli negli ultimi tre mesi e conferma l'assenza di informazioni materiali avverse non divulgate.

Aviso Form 144 de CryoPort, Inc. (CYRX): La presentación informa sobre la propuesta de venta de 9.300 acciones ordinarias, con un valor de mercado agregado de $80.617,98, de un total de 50.066.968 acciones en circulación. Las acciones se venderán el 08/19/2025 en el NASDAQ a través de Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. La declaración indica que las acciones se adquirieron el 08/19/2025 mediante el ejercicio de opciones bajo un plan registrado y se pagaron en efectivo. El declarante informa que no vendió valores en los últimos tres meses y afirma que no existe información adversa material no divulgada.

CryoPort, Inc. (CYRX) Form 144 공지: 제출 서류는 총 발행주식 50,066,968주 중 9,300 보통주를 매도할 예정이며, 총 시장가치는 $80,617.98라고 보고합니다. 해당 주식은 08/19/2025NASDAQ에서 Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY를 통해 매도될 예정입니다. 서류에 따르면 주식은 08/19/2025에 등록된 플랜에 따른 옵션 행사로 취득되었고 현금으로 지급되었다고 합니다. 제출자는 최근 3개월간 매도한 증권이 없음을 보고하고, 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.

Avis Form 144 de CryoPort, Inc. (CYRX) : Le dépôt signale la vente proposée de 9 300 actions ordinaires, pour une valeur marchande totale de 80 617,98 $, sur un total de 50 066 968 actions en circulation. Les actions doivent être vendues le 08/19/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. Le document indique que les actions ont été acquises le 08/19/2025 par exercice d’options dans le cadre d’un plan enregistré et ont été payées en espèces. Le déclarant indique n’avoir vendu aucun titre au cours des trois derniers mois et affirme qu’il n’existe aucune information défavorable matérielle non divulguée.

Form 144-Mitteilung von CryoPort, Inc. (CYRX): Die Einreichung meldet einen geplanten Verkauf von 9.300 Stammaktien mit einem kumulierten Marktwert von $80.617,98 aus insgesamt 50.066.968 ausstehenden Aktien. Die Aktien sollen am 08/19/2025 an der NASDAQ über Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY verkauft werden. In der Einreichung heißt es, die Aktien seien am 08/19/2025 durch Ausübung von Optionen im Rahmen eines registrierten Plans erworben und in Barkasse bezahlt worden. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und bestätigt, dass keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the CYRX Form 144 report?

The filing reports a proposed sale of 9,300 common shares of CryoPort (CYRX) with an aggregate market value of $80,617.98 to be sold on 08/19/2025 on NASDAQ.

How were the CYRX shares acquired?

The shares were acquired on 08/19/2025 by exercise of options under a registered plan and payment was made in cash.

Which broker will execute the CYRX sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY.

Were any CYRX shares sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

What attestation does the filer make on the Form 144?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.
Cryoport Inc

NASDAQ:CYRX

CYRX Rankings

CYRX Latest News

CYRX Latest SEC Filings

CYRX Stock Data

436.58M
47.50M
3.78%
100.67%
5.8%
Integrated Freight & Logistics
Pharmaceutical Preparations
Link
United States
BRENTWOOD